Articles tagged with Radiation Therapy
A natural citrus oil, when combined with a lipid formulation, may effectively relieve dry mouth in cancer patients. The new formula has demonstrated improved solubility and bioavailability compared to pure limonene.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
Researchers have uncovered a key mechanism involving Intermolecular Coulombic Decay (ICD) in aqueous environments initiated by heavy-ion irradiation, providing insights into the effectiveness of such irradiation. This process significantly increases the biological effectiveness of heavy-ion therapy.
A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.
The NRG Oncology GOG-0263 phase III clinical trial found that adding cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy did not improve outcomes and led to increased toxicity. Radiotherapy alone remains the standard of care for early-stage, intermediate-risk cervical cancer.
Researchers found that the current standard monitoring time of one-and-a-half to two months following surgery is too short to accurately identify recurrence and inform treatment decisions. Monitoring PSA levels for at least three months can avoid overtreatment and mislabel patients as having recurred.
Researchers at Waseda University develop a new imaging technique that uses neutron activation to transform gold nanoparticles into radioisotopes, enabling long-term tracking of their movement in the body. This breakthrough could lead to more effective cancer treatments and precision monitoring of drug distribution.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.
A recent study by Professor Mamas highlights the significant risk of cardiovascular diseases (CVD) in patients with cancer, particularly in aging populations. The review emphasizes the need for early diagnosis and regular monitoring to improve quality of life.
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
Researchers combine radiation with a plant-derived compound to combat glioblastoma, forcing cancer cells into a dormant state. The approach significantly slows tumor growth and improves survival in mice models, offering a potential new avenue for combating this deadly form of brain cancer.
A consensus statement by the Chinese College of Interventionalists promotes CBCT use in liver malignancy therapies, addressing limitations and challenges. The integration of artificial intelligence and technological innovations are expected to refine CBCT's efficacy and safety.
Researchers investigated radiation-induced cardiomyopathy management strategies to mitigate cardiac damage. The review discusses pathophysiology, clinical implications, and treatment options, including antioxidant medications and herbal supplements.
A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.
Researchers found that radiation combined with immune checkpoint inhibitors durvalumab and tremelimumab resulted in durable responses allowing for bladder preservation in localized MIBC patients. The study showed a high efficacy rate of 93% complete response rate, with 84% overall survival rate after two years.
ABT-263 eliminates harmful aging cells in the gut, reducing inflammation and lowering cancer risk in a mouse model of GI cancer. The study suggests that removing senescent cells could help prevent radiation-related GI cancer, highlighting the potential of senolytic drugs as a preventive treatment.
Researchers at Huntsman Cancer Institute found that short-course, higher dose vaginal brachytherapy for endometrial cancer was as effective as more frequent, lower dose sessions in similar outcomes and few acute toxicities. The study aims to improve cancer care for patients across the Mountain West region.
A new Phase I clinical trial from London Health Sciences Centre Research Institute found high-precision radiation therapy to be safe in treating patients with polymetastatic disease. The study, known as ARREST, used stereotactic ablative radiotherapy (SABR) to treat cancer that has spread to more than 10 spots in the body.
Researchers developed a novel microscopy technique to study metabolic changes in individual cancer cells at the single-cell level. They found that radiation treatment caused significant metabolic shifts in head and neck squamous cell carcinoma cells, particularly through the activation of HIF-1α.
A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...
A novel approach transforms treatment for pancreatic cancer by repurposing WR-2721 to protect healthy tissue from radiation damage. Phase 1 and 2 clinical trials are underway to evaluate the safety and efficacy of the new therapy, which could add years of survival to patients.
Researchers from Tokyo Metropolitan University developed a new dye that strongly absorbs second near-IR radiation, transforming it to heat. This breakthrough enables clearer imaging and better delivery of heat for therapies in deep tissue medicine.
The Varian Ethos 2.0 system enables precise and adaptive radiation therapy for multiple types of cancer, including prostate, lung, breast, and others. This technology allows for personalized treatment plans to be updated daily to match the changing anatomy of the patient.
A phase III trial found that combining radiotherapy with cetuximab improved disease-free survival in patients with HPV-negative head and neck cancer, but not overall survival. The treatment was also associated with higher rates of acute toxicity.
Researchers discovered that DNA repair determines how cancer cells die following radiotherapy, with specific pathways triggering cell death noticed by the immune system. Blocking these pathways can force cancer cells to die in a manner that alerts the immune system, leading to new potential treatments.
Researchers developed a new type of plastic scintillator that offers improved optical clarity, mechanical strength, and detection accuracy. This advancement has the potential to create next-generation radiation detectors that are safer, stronger, and more cost-effective.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
A new ASTRO survey finds that prior authorization delays lead to treatment interruptions, hospitalizations, and patient deaths. The problem is worsening, with patients experiencing longer treatment delays than during the COVID-19 pandemic.
Combining PVA with a boron-containing compound improved the effects of radiation therapy for cancer, making it more selective of tumor cells and prolonging drug retention. This breakthrough could lead to more effective treatment options for challenging cancers.
A randomized phase 3 trial found that adding temozolomide to radiation therapy improves long-term survival for adult patients with low-grade gliomas. The 10-year survival rate was 70% with combined treatment, compared to 47% with radiation alone.
The updated ASTRO guideline recommends personalized treatment approaches for patients with locally advanced rectal cancer, including non-surgical alternatives and intensified treatment regimens. The guideline aims to improve outcomes while preserving quality of life.
A phase II clinical trial showed that combining radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, resulting in significantly improved outcomes. The study found that patients who underwent surgery had a 82% reduction in risk of death at one year follow-up.
Patients receiving MRI-guided SBRT experienced significantly fewer urinary and bowel side effects compared to CT-guided treatment. MRI guidance also correlated with improved scores on specific quality-of-life measures, including bowel function and sexual health.
A new clinical trial found that the addition of immunotherapy drug pembrolizumab to standard treatment improved disease-free survival rates for patients with stage 3 soft tissue sarcoma. The study showed that pembrolizumab reduced recurrence or death for patients by 15 percentage points compared to standard treatment.
Researchers found that non-invasive stereotactic radiosurgery significantly improves tumor control and reduces symptoms such as tinnitus, cranial nerve deterioration, and vestibular dysfunction. Early treatment can prevent tumors from growing over time and spare patients from irreversible problems.
A comprehensive analysis of 52,000 men with prostate cancer treatment found substantial long-term risks of urinary and sexual complications. Men treated with radiotherapy faced a threefold risk of bladder cancer diagnosis, while those who underwent prostatectomy had a sixfold increased risk of complications.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
Researchers at Osaka University demonstrated that ultra-short, high-dose proton irradiation increases cell survival rates even under normoxic conditions. This breakthrough could lead to the development of a cancer treatment method with fewer side effects.
Researchers have found that tumors with a short-lived response to hormone therapy had a mutation in the p53 gene, which can be targeted by CDK2 inhibitors. A new study also provides updated dosing guidelines for stereotactic body radiation therapy (SBRT) to minimize complications in patients with spinal metastasis.
Children who survived childhood brain cancer are more likely to struggle academically, with a greater chance of being held back and performing poorly on state testing. The study's findings highlight the need for better support and resources to help these students succeed.
Researchers at Jefferson Lab's BRIC are assessing proton therapy's potential to replace radioisotope-based treatments, with a focus on reducing radiological risks. The study aims to bridge the gap between nuclear physics and medical professionals, exploring proton therapy's capabilities for cancer treatment.
A new study found that common breast cancer treatments, including chemotherapy, radiation, and surgery, can increase expression of aging markers in breast cancer survivors. The study suggests that these treatments can have a more extensive impact on the body than previously thought, leading to accelerated biological aging.
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Natural Killer (NK) cell-based therapies have shown promise in preclinical and clinical studies for treating Acute Myeloid Leukemia (AML), offering a potential cure with minimal prior antigen sensitization. However, the dysfunction of NK cells in AML patients poses a significant challenge that must be overcome to unlock their full ther...
A survey found that spiritual beliefs and distrust of clinical research contribute to Black patients' hesitation to enroll in cancer trials. Despite trusting their medical teams, some patients express concerns about the purpose of research and its potential impact on their health and community.
A new study by Sylvester Comprehensive Cancer Center researchers shows that daily MRI imaging paired with radiation can monitor tumor changes in real-time. The technology has the potential to signal early warning signs of tumor growth, allowing for faster and more targeted treatment adaptations.
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
A new study found that hypofractionation does not increase complications for patients with breast cancer who undergo mastectomy and plan breast reconstruction. The trial enrolled 898 patients and showed that reducing treatment time by nearly half is safe and effective, saving patients time and money.
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.